Opioid drugs addiction release prevention and the cure of alcohol dependence
Naltrexone is an opioid receptor antagonist, andcombination with opioid receptor activity is 30 times more than heroin opioid drugs, Therefore, when naltrexone reaches a certain concentration in the body, that can effectively antagonize most opioid receptors. As a result, drugs such as heroin cannot produce euphoria, and the drugs block the production of drug use pleasure to achieve the anti-relapse treatment effect.
SK1805 is the central excipients of Naltrexone Implant and other projects，a polymer biodegradable absorbent material, used to wrap drugs into microspheres to control slow drug release. At present, the research and development of large-scale self-synthesis has been successfully completed, and the industrialization is expected to be completed simultaneously with the naltrexone implant.
The nemesis of new drugs such as amphetamine and magu
SK1908 is an improved new drug project for the prevention and relapse treatment of new drug addiction dependence such as smokable methamphetamine, ketamine, and cocaine. The global initiative. It uses a chemical drug compound to technically control the release of the two drugs at the same release rate for 3 More than months. SK1908 has made major breakthroughs and achieved the expected results. In the future, pre-clinical work such as pilot trials and animal evaluations will be carried out. It is expected to apply for clinical trials within two years.
SK2005 is a µ opioid receptor semi-agonist, used for maintenance treatment of drug users，It is a long-acting micro-implant that can be released for 3 months and can be directly administered by subcutaneous injection for better compliance. SK2005 has low addiction and can replace methadone in the community or voluntary detoxification. It has good prospects
Increasing new indications for the treatment of alcohol dependence, targeting the soft drug market
Eliminating alcohol dependence is another indication for which naltrexone has been approved for marketing. This project will extend naltrexone implants to the treatment of alcohol dependence. In 2021, SK2007 will apply for phase II clinical trials and is expected to complete phase II trials in 2023.
This project is a new type of compound inhaler for the treatment of depression. The purpose is to solve the shortcomings of slow onset of common antidepressant drugs. For major depression or refractory depression, especially depression with suicidal tendency. By inhaling antidepressant drugs, it takes effect quickly, relieves depression and depression in a few minutes, and prevents suicide and self-harm. This species will make a considerable contribution to the development of antidepressant drugs.
Advisory
